TY - JOUR
T1 - Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring
T2 - A CRUSE® mobile health study
AU - Sousa-Pinto, Bernardo
AU - Ramanauskaite, Aiste
AU - Neisinger, Sophia
AU - Witte-Händel, Ellen
AU - Gimenez-Arnau, Ana M.
AU - Guillet, Carole
AU - Parisi, Claudio Alberto S.
AU - Katelaris, Constance H.
AU - Fomina, Daria
AU - Larenas-Linnemann, Désirée
AU - García, Elizabeth
AU - Kocatürk, Emek
AU - Siebenhaar, Frank
AU - Lima, Hermenio
AU - Kaidashev, Igor
AU - Nasr, Iman
AU - Canales, Isabel Ogueta
AU - Ojeda, Ivan Cherrez
AU - Hébert, Jacques
AU - Bousquet, Jean
AU - Bernstein, Jonathan A.
AU - Peter, Jonny
AU - Sanchez, Jorge
AU - Sousa, Jose Ignacio Larco
AU - Kulthanan, Kanokvalai
AU - Weller, Karsten
AU - Godse, Kiran
AU - Rutkowski, Krzysztof
AU - Lapina, Lasma
AU - Bouillet, Laurence
AU - Han, Leo Lianyi
AU - Ensina, Luis Felipe
AU - Gonçalo, Margarida
AU - Magerl, Markus
AU - van Doorn, Martijn
AU - Metz, Martin
AU - Khoshkhui, Maryam
AU - Hide, Michihiro
AU - Türk, Murat
AU - Kurjāne, Nataļja
AU - Conlon, Niall
AU - Salameh, Pascale
AU - Kolkhir, Pavel
AU - Asero, Riccardo
AU - Stepanenko, Roman
AU - Altrichter, Sabine
AU - Gil-Mata, Sara
AU - Thomsen, Simon Francis
AU - Zuberbier, Torsten
AU - Tsaryk, Vladyslav
AU - Ye, Young Min
AU - Brzoza, Zenon
AU - Zhao, Zuotao
AU - Maurer, Marcus
N1 - Publisher Copyright:
© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2024
Y1 - 2024
N2 - Background: CRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs. Methods: We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU (‘VAS urticaria’), VAS for the impact of urticaria on work/school productivity (‘VAS productivity’) and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test–retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods. Results: We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test–retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D. Conclusion: Daily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test–retest reliability and responsiveness.
AB - Background: CRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs. Methods: We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU (‘VAS urticaria’), VAS for the impact of urticaria on work/school productivity (‘VAS productivity’) and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test–retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods. Results: We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test–retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D. Conclusion: Daily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test–retest reliability and responsiveness.
KW - mHealth
KW - patient-reported outcome measures
KW - urticaria, chronic spontaneous urticaria
UR - http://www.scopus.com/inward/record.url?scp=85207494050&partnerID=8YFLogxK
U2 - 10.1111/all.16371
DO - 10.1111/all.16371
M3 - Journal article
C2 - 39445583
AN - SCOPUS:85207494050
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0105-4538
ER -